Lutathera^® Orphans: State of the Art and Future Application of Radioligand Therapy with ¹⁷⁷Lu-DOTATATE

• Main Authors: Luca Urso (Author), Alberto Nieri (Author), Licia Uccelli (Author), Angelo Castello (Author), Paolo Artioli (Author), Corrado Cittanti (Author), Maria Cristina Marzola (Author), Luigia Florimonte (Author), Massimo Castellani (Author), Sergio Bissoli (Author), Francesca Porto (Author), Alessandra Boschi (Author), Laura Evangelista (Author), Mirco Bartolomei (Author)
• Format: Book
• Published: MDPI AG, 2023-03-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Lutathera^® is the first EMA- and FDA-approved radiopharmaceutical for radioligand therapy (RLT). Currently, on the legacy of the NETTER1 trial, only adult patients with progressive unresectable somatostatin receptor (SSTR) positive gastroenteropancreatic (GEP) neuroendocrine n...